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Abstract 
Aims: Smoking is a major preventable risk factor for cardiovascular disease and mortality. 
However, the ‘smoker’s paradox’ suggests that it is associated with better survival after acute 
myocardial infarction. We aimed to investigate the impact of smoking on mortality and 
cardiovascular outcomes in patients with stable coronary artery disease. 
 
Methods: The international CLARIFY registry included 32,703 patients with stable coronary artery 
disease between 2009 and 2010. Among the 32,378 patients included in the present analysis, Cox 
proportional hazards models (adjusted for age, sex, geographic region, prior myocardial infarction, 
and revascularization status) were used to estimate associations between smoking status and 
outcomes. Patients were stratified as follows: 41.3% of patients never smoked, 12.5% were current 
smokers and 46.2% were former smokers. 
 
Results: Current smokers were younger than never-smokers and former smokers (59 vs. 66 and 64 
years old, respectively, p<0.0001). There were more men among current or former smokers 
compared with never-smokers. Compared with never-smokers, both current and former smokers 
were at higher risk of all-cause death (hazard ratio.1.96 and 1.37) and cardiovascular death (hazard 
ratio.1.92 and 1.38) within five years (all p<0.05). Similarly graded and increased risks were 
present for myocardial infarction and the composite of cardiovascular death, myocardial infarction 
and stroke (all p<0.05). 
 
Conclusion: In contrast to the ‘smoker’s paradox’, current smokers with stable coronary artery 
disease have a greatly increased risk of future cardiovascular events, including mortality, compared 
with never-smokers. In former smokers, cardiovascular risk remains elevated albeit at an 
intermediate level between that of current and never-smokers, reinforcing the importance of 
smoking cessation. (ISRCTN43070564). 
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Introduction 
Tobacco remains the leading cause of preventable death in Western countries. It is responsible for 
700,000 deaths a year in Europe,1 and it accounts for substantial increases in preventable 
cardiovascular mortality and disability.2–7 Therefore, reduction of tobacco use is an important 
health priority. However, the extent to which its use and cessation impacts morbidity and mortality 
in patients with stable coronary artery disease (CAD) receiving contemporary medical therapy 
warrants further study. Indeed, confusing data regarding the so-called ‘smoker’s paradox’,8 which 
refers to the seemingly better survival of smokers early after an acute myocardial infarction, may 
have to some extent limited the effectiveness of secondary prevention.8–10 
 
The prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY 
disease (CLARIFY) registry aims to improve knowledge on the contemporary management and 
outcomes of both symptomatic and asymptomatic patients with stable CAD.11 This large 
international registry provides detailed information on clinical and biological characteristics, 
medications and yearly outcomes, up to five years.11 In the present analysis, we aimed to assess 
the contemporary impact of smoking status at baseline on cardiovascular outcomes in patients with 
stable CAD receiving contemporary treatment. 
 
Methods 
Study design and population 
CLARIFY is an international registry which included outpatients with stable CAD receiving 
contemporary treatment and followed up yearly for up to five years. The rationale and design of 
the study have been previously described.11 A total of 32,703 patients were enrolled in 45 countries 
in Africa, Asia, Australia, Europe, the Middle East, and North, Central and South Americas. All 
patients gave written informed consent, and ethics approval was obtained in all participating 
countries in accordance to local regulations. 
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Patient demographics, clinical profile, ongoing therapies and clinical outcomes were prospectively 
collected in order to provide reliable information with regard to the contemporary management of 
stable CAD worldwide. Physicians, including cardiologists, general practitioners, internists and 
hospital-based physicians, were selected in order to provide a representative distribution of 
healthcare providers in each country. This selection process was validated by the study executive 
committee, and physicians were instructed to manage their patients according to usual practice 
regardless of their enrolment in the present registry.11 
Inclusion and exclusion criteria have been detailed previously.11,12 Briefly, patients were recruited 
between November 2009 and July 2010 if they had stable CAD defined according to the presence 
of at least one of the following: (a) documented myocardial infarction (MI) at least three months 
before enrolment; (b) angiographic demonstration of coronary artery stenosis of at least 50% in at 
least one vessel; (c) history of chest pain with evidence of myocardial ischaemia proven by either 
stress electrocardiogram, stress echocardiography or stress myocardial perfusion imaging; (d) 
coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI) at least 
three months before enrolment. Patients were excluded if they had a history of hospitalization for 
cardiovascular disease within the past three months (including revascularization), planned 
myocardial revascularization or any condition hampering follow-up, including any severe 
cardiovascular and non-cardiovascular conditions potentially interfering with life expectancy (e.g. 
cancer or advanced heart failure) within the following five years. 
 
Outcomes 
Clinical events were collected as reported by investigators without central adjudication.11 The 
main outcomes included mortality and cardiovascular morbidity data. Cardiovascular deaths were 
categorized into fatal MI, fatal stroke and other cardiovascular deaths (including sudden cardiac 
death and deaths from unknown cause). Non-cardiovascular deaths were any deaths that were not 
classified as related to a cardiovascular cause. Non-fatal events included non-fatal MI, non-fatal 
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stroke and coronary revascularization (PCI and CABG). Non-fatal events collected were mostly 
non-fatal MI, unstable angina, new-onset or worsening heart failure requiring hospitalization, 
coronary revascularization, non-fatal stroke or transient ischaemic attack and major bleeding. 
 
Statistical analysis 
Data were centrally analyzed by an academic statistics center (Robertson Centre for Biostatistics, 
University of Glasgow, UK). Baseline characteristics are summarized using counts and percentages 
for categorical variables and mean +/- standard deviation (SD) or median (interquartile range 
(IQR)) for continuous variables. Comparisons were made according to smoking status at baseline: 
current smokers were defined as subjects who had smoked during the month before the visit; former 
smokers had stopped smoking more than one month before enrolment; and never-smokers had 
never smoked. Comparisons were made using chi-square tests, one-way analysis of variance or 
Kruskal–Wallis tests, as appropriate. The effects of smoking status on clinical outcomes were 
determined using Cox proportional hazards models adjusted solely for age as well as for major 
clinical variables known to be associated with prognosis; including cardiovascular risk factors, 
geographic region, prior MI, and revascularization status (PCI and CABG). Data were analyzed as 
recorded, without imputation for missing data. Unadjusted hazard ratios and corresponding 95% 
confidence intervals are not provided owing to the confounding association between smoking 
information and other baseline characteristics. Hazard ratios and 95% confidence intervals were 
determined, and p-values calculated from the Wald statistic. p-values <0.05 were considered to be 
statistically significant. The analysis for this paper was generated using SAS software version 9.3. 
Copyright 2002-2010 SAS Institute Inc. SAS and all other SAS Institute Inc. product or service 
names are registered trademarks or trademarks of SAS Institute Inc., Cary, North Carolina, USA. 
 
Results 
Baseline characteristics 
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Of the total of 32,703 patients enrolled in the CLARIFY registry, 32,378 patients had available 
information on smoking status and were included in the present analysis. Patients were distributed 
as follows: 41.3 never smoked, 12.5% were current smokers and 46.2% were former smokers. The 
median (IQR) duration from CAD diagnosis to year of enrolment in the study is 5.0 (2.0; 9.0) years. 
Overall, patients were predominantly males (78%) with a mean age of 64 years and multiple 
cardiovascular risk factors; 71% were treated for hypertension, 29% had diabetes and 75% 
dyslipidaemia; 60% of patients had prior MI and 75% had a history of myocardial revascularization 
(either CABG or PCI). Patients were mostly asymptomatic, 85% had no heart failure and 78% had 
no angina, while patients were under well-conducted medical therapy in general (88% were treated 
with aspirin, 75% had beta-blockers and 92% lipid-lowering drugs; Table 1). 
 
Baseline characteristics according to smoking status 
Current smokers were younger than both never smokers and former smokers (59 vs. 66 and 64 
years respectively, p<0.0001; Table 1). There were more men among current or former smokers 
compared with never-smokers (87% and 90% vs. 61%, p<0.0001). Current and former smokers 
had a higher prevalence of previous MI in comparison with their never-smoker counterparts. 
Notably, patients with recent smoking cessation (<5 years) had the highest revascularization rates 
(either PCI or CABG) in comparison with other groups (according to timing of smoking cessation 
and daily tobacco consumption; Supplemental Material online, Table S-1). 
 
Rates of clinical events according to smoking status 
After a median follow-up (IQR) of 5.0 (4.4; 5.1) years, 7.1% of patients who never smoked, 8.1% 
of current smokers and 8.5% of former smokers died from all causes. Cardiovascular death occurred 
in 4.5%, 5.1% and 5.4% of never-smokers, current and former smokers, respectively. Rates of fatal 
or non-fatal MI were 2.8, 4.3 and 3.7% respectively in the three groups. The composite of 
cardiovascular death or MI occurred in 6.3% of never-smokers, 8.3% of current smokers and 7.8% 
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of former smokers, while the composite of cardiovascular death, MI or stroke was observed in 7.8, 
9.7 and 9.2%, respectively. The composite of cardiovascular death, MI, coronary revascularization 
or stroke occurred in 13.5%, 15.6 and 15.2% of patients (online Supplemental Table S-1). 
 
Rates of clinical events according to duration of smoking cessation and cigarettes daily 
consumption 
Clinical events according to time of smoking cessation for former smokers and daily tobacco 
consumption for current smokers are provided in online Supplemental Table S-1. All-cause death 
occurred in 10.3%, 7.7% and 6.2% of former smokers who had quit smoking >9 years, 5–9 years 
and <5 years ago; cardiovascular death in 6.6%, 5.1% and 3.8% and non-cardiovascular death in 
3.8%, 2.6% and 2.4% respectively. Regarding the daily cigarette consumption (>10 cigarettes 
smoked per day vs. 1–10), all-cause deaths occurred in 7.6% vs. 8.5%, respectively; cardiovascular 
deaths in 4.8% vs. 5.4% respectively, and the rates of MI (fatal or nonfatal) were 4.2% vs. 4.4%, 
respectively. 
 
Clinical outcomes according to smoking status 
The associations between smoking status and clinical outcomes are shown in Table 2, adjustments 
being made for age, sex, geographic region, prior MI, and revascularization status. Compared with 
never smokers, both current and former smokers were at higher risk of all-cause death (adjusted 
hazard ratio = 1.96 and 1.37, respectively, p<0.0001) and cardiovascular death (adjusted hazard 
ratio = 1.92 and 1.38, respectively, p<0.0001). Similarly graded and increased risks were present 
for MI and composite endpoints (all p<0.05). The risk of fatal or non-fatal MI was increased in 
current smokers (adjusted hazard ratio = 1.69) and former smokers (adjusted hazard ratio = 1.28). 
The risk of the composite endpoint of cardiovascular death or MI was raised in both current 
(adjusted hazard ratio¼1.86) and former smokers (adjusted hazard ratio = 1.34), while that of the 
composite of cardiovascular death, MI or stroke was also higher (adjusted hazard ratio = 1.73 and 
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1.28 respectively) compared with never-smokers. Finally, the risk of the composite of 
cardiovascular death, MI, coronary revascularization or stroke was significantly increased in both 
current smokers (adjusted hazard ratio = 1.36) and former smokers (adjusted hazard ratio = 1.17). 
These associations remained significant when adjusting for age only (online Supplemental Table 
S-2).  
Clinical outcomes according to duration of smoking cessation and cigarette daily consumption 
Regarding duration of smoking cessation, patients with <5 years, 5–9 years or >9 years of smoking 
cessation remained at higher risks of all-cause deaths (adjusted hazard ratio = 1.51, 1.41 and 1.30, 
respectively), cardiovascular deaths (adjusted hazard ratio = 1.42, 1.46 and 1.35, respectively), and 
non-cardiovascular deaths (adjusted hazard ratio = 1.69, 1.33 and 1.23, respectively) when 
compared with non-smokers (Table 3). When compared with non-smokers, active smoking was 
consistently associated with graded worse outcomes in CLARIFY, regardless of the amount of 
smoked cigarettes per day (>10 or <10 cigarettes per day; Table 3), with a significant association 
with all-cause mortality (adjusted hazard ratio = 2.14 and 1.88, respectively), cardiovascular-
mortality (adjusted hazard ratio = 2.07 and 1.83, respectively), non-cardiovascular mortality 
(adjusted hazard ratio = 2.29 and 1.97, respectively) and fatal or non-fatal MI (adjusted hazard ratio 
= 1.71 and 1.66. respectively). 
 
Discussion 
This is the largest cohort analysis of the impact of smoking status on cardiovascular outcomes in 
patients with stable CAD receiving contemporary treatment who were included in the CLARIFY 
registry. The main observations from the present analysis are that: (a) active smoking remains 
strongly associated with poor cardiovascular outcomes; (b) although former smokers are at lower 
risk than active smokers, they remain at higher risk for major clinical outcomes when compared 
with patients who never smoked; (c) the adjusted hazard ratio for the composite of cardiovascular 
death, MI and stroke was 1.73 (1.53; 1.96) for current smokers compared with never smokers (after 
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adjusting for age, sex, geographic region, prior MI, prior PCI and prior CABG), indicating that the 
potential harm associated with continued smoking vastly exceeds the benefits related to evidence-
based therapies in this population. 
 
Impact of smoking status on major outcomes 
In this study, we demonstrate that active smoking remains a major determinant of both all-cause 
and cardiovascular mortality in a contemporary cohort of relatively young patients with CAD and 
no other major comorbidity. In the Coronary Artery Surgery Study cohort,13 survival was 
significantly better in never smokers when compared with current smokers (80% and 77%, 
respectively). In a post-hoc analysis of the Treating to New Targets study14 and the Incremental 
Decrease in End Points Through Aggressive Lipid Lowering study, smoking cessation in patients 
with stable CAD was demonstrated to provide an absolute decrease of 4.5% in the occurrence of 
the composite end-point of cardiac death, myocardial infarction, stroke or resuscitated cardiac 
arrest.15,16 As such, the number needed to treat to prevent one major cardiovascular event was 
shown to be as low as 22 among patients also receiving intensive statin therapy,16 and the 
protective effect associated with smoking cessation was demonstrated to exceed that achieved by 
conventional medical treatments in various settings, including patients with chronic cardiovascular 
disease.17 The harmful effects of smoking were shown to be additive to those of other 
cardiovascular risk factors.18 In CLARIFY, up to 25% of current smokers also suffered from 
diabetes, 64% had hypertension and 73% dyslipidaemia. Although the combined effects of current 
smoking and other risk factors were not analyzed in CLARIFY, a recent meta-analysis of 89 cohort 
studies demonstrated that smoking was associated with nearly half of the increase in cardiovascular 
deaths and all-cause mortality among diabetic patients.19 
 
Clinical outcomes according to the duration of smoking cessation 
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In the present study, we demonstrate that although at lower risk in comparison with active smokers, 
former smokers remain at higher risk for major outcomes regardless of the timing of smoking 
cessation within the duration of smoking cessation that was examined in this work. As such, 
patients in CLARIFY who have stopped smoking for>9 years are still at high risk for cardiovascular 
deaths with adjusted hazard ratio 1.35 (1.18; 1.54), comparison being made with non-smokers. 
Although previous studies have provided evidence that smoking cessation yields a significant 
benefit that may manifest rapidly after quitting,17 with a 50% decrease in cardiovascular risk 
reported after one year of smoking cessation,20,21 our results highlight the long-lasting effects of 
smoking on cardiovascular outcomes for longer periods of smoking cessation. Our results are in 
line with the most recent cohort analysis where the risk related to smoking lasted for>20 years for 
coronary heart disease in patients from the Atherosclerosis Risk In Communities study without 
baseline atherosclerotic disease.22 
 
Clinical outcomes according to cigarettes daily consumption 
In this study, we observed that active smoking is consistently associated with poor outcomes among 
a contemporary cohort of patients with stable CAD, even in light smokers. Risks associated with 
light smoking have also been shown by others, with light smokers being at higher risk for 
cardiovascular mortality as well as all-cause mortality in comparison with non-smoking 
individuals. 23–25 This association between cardiovascular outcomes and light smoking is all the 
more important in terms of counselling and healthcare prevention policies, as it highlights the 
harmful impact of any level of smoking on cardiovascular outcomes. As such, smoking cessation 
rather than smoking reduction should always be strongly encouraged in patients with stable CAD. 
 
Clinical perspectives 
This study provides important insights with regard to cardiovascular outcomes according to 
smoking status in patients with stable CAD. Although cardiovascular risk significantly declined 
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after smoking cessation in comparison with current smokers, former smokers still demonstrate a 
significantly higher risk of poor cardiovascular outcomes, even for long durations of smoking 
cessation, when compared with their never smoked counterparts. These results further highlight 
the need for more aggressive smoking prevention policies. 
 
Study limitations 
The present study has limitations. Smoking status was determined at one time point (baseline) and 
then reassessed yearly during follow-up. Smoking relapse during follow-up was not analyzed, due 
to the small numbers of patients changing in the groups of interest. There was no central 
adjudication of the clinical events that were reported by the local investigators. Yet, the associations 
observed between baseline smoking status and adverse cardiovascular outcomes were robust and 
consistent throughout the entire range of events, including all-cause mortality (where adjudication 
is immaterial). This being said, this is the largest cohort analysis regarding the contemporary 
impacts of smoking status on cardiovascular outcomes in well-treated patients with stable CAD (in 
contrast to most prior analyses, in which the use of antiplatelet therapy and statins was low).23 
 
Conclusion 
In contrast to the ‘smoker’s paradox’ reported after acute MI, and despite high rates of use of 
evidence-based preventive therapies, current smokers with stable CAD have a greatly increased 
risk of future cardiovascular events compared with never-smokers. Cardiovascular risk remains 
elevated in former smokers, albeit at an intermediate level between that of current and never-
smokers, reinforcing the importance of smoking cessation in patients receiving contemporary 
management for stable CAD. 
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